-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QZW4NCJDIbz53ay9S91dLqOCf5tjO+xiFyRtOFoFcncC7gglKpSa+Wg7U3LfaQCh
 82UBm7JWTWTlQ/dvMtdmfw==

<SEC-DOCUMENT>0001075880-05-000028.txt : 20050902
<SEC-HEADER>0001075880-05-000028.hdr.sgml : 20050902
<ACCEPTANCE-DATETIME>20050902080136
ACCESSION NUMBER:		0001075880-05-000028
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20050902
FILED AS OF DATE:		20050902
DATE AS OF CHANGE:		20050902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		051066083

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050902.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 2 September, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
2 SEPTEMBER 2005

Novogen announces development and expansion of U.S. subsidiary companies

(SYDNEY, Australia and STAMFORD, Conn., September 2, 2005)  Novogen Limited
(NASDAQ:  NVGN; ASX:  NRT) today announced the expansion in the U.S. of
Glycotex, Inc., its U.S. subsidiary, and the resignation of
Dr. Graham Kelly from Novogen's Board of Directors in order
for him to focus on the development and expansion of Novogen's U.S.
subsidiary companies.

Glycotex, Inc.'s business is based on the development of wound healing
glucan compounds, particularly the Company's glucan technology that has
been licensed by Novogen to Glycotex.
Dr. Kelly developed the intellectual property used by Glycotex.

In addition to contributing to Glycotex's expansion, Dr. Kelly serves
as the Chairman and Oncology Project Director of Novogen's U.S. subsidiary,
Marshall Edwards, Inc. (NASDAQ:  MSHL; LSE/AIM:  MSH),
where he is responsible for the development of its investigational
anti cancer drug phenoxodiol.  Marshall Edwards is currently embarking
on multi center, international pivotal clinical trials of phenoxodiol
that are centered in the United States and Europe and have a growing
need for greater supervision in the lead-up to registration submissions.

"The focus of the Glycotex and Marshall Edwards R&D activities in the
U.S. and Europe means that I have to be there in order to manage their
growth," said Dr. Kelly.  "Standing down from the Novogen Board will
make that easier for me."

Accordingly, Dr. Kelly will be required to spend a significant
amount of time in the United States and Europe.  Although Dr. Kelly
has relinquished his directorship of Novogen, he will continue in
his executive role in Novogen and will retain his Chairmanship of
Marshall Edwards Inc.

Novogen is involved in drug discovery and product development for
disorders that are commonly associated with aging, and coordinates
an international clinical research and development program with
external collaborators, hospitals and universities.
Phenoxodiol is an investigational drug and, as such, is not
marketed in the U.S.


Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in this
press release that are not historical in nature are "forward-looking
statements" within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. You should
be aware that our actual results could differ materially from
those contained in the forward-looking statements, which are based
on management's current expectations and are subject to a number of
risks and uncertainties, including, but not limited to, our failure
to successfully commercialize our product candidates; costs and delays
in the development and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual
arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents
and proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes;
government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors
or to publicly announce the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
